Conivaptan

Conivaptan

Systematic (IUPAC) name
N-(4-(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin- 6(1H)-yl)carbonyl)phenyl)- (1,1'-biphenyl)-2-carboxamide
Clinical data
AHFS/Drugs.com	monograph
Pregnancy cat.	?
Legal status	?
Routes	intravenous
Pharmacokinetic data
Bioavailability	N/A
Identifiers
CAS number	210101-16-9
ATC code	C03XA02
PubChem	CID 151171
DrugBank	DB00872
ChemSpider	133239 Y
UNII	0NJ98Y462X Y
KEGG	D01236
ChEBI	CHEBI:681850 Y
ChEMBL	CHEMBL1755 Y
Chemical data
Formula	C32H26N4O2
Mol. mass	498.583
SMILES	eMolecules & PubChem
InChI InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37) Y Key:IKENVDNFQMCRTR-UHFFFAOYSA-N Y
Y(what is this?)  (verify)

Conivaptan (YM 087, brand name Vaprisol) is a non-peptide inhibitor of antidiuretic hormone (vasopressin receptor antagonist). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH), and there is some evidence it may be effective in heart failure. It is marketed by Astellas Pharma Inc.

Conivaptan inhibits two of the three subtypes of the vasopressin receptor (V1a and V2). Effectively, it causes iatrogenic nephrogenic diabetes insipidus.

Conivaptan has not been approved by the FDA for the treatment of decompensated congestive heart failure. However, in theory, vasopressin receptor antagonism would be particularly useful in this setting, and an initial study shows that it has some promise.